VOR — Vor Biopharma Inc
NASDAQ · Healthcare · Biotechnology
$24.07
+$1.43 (+6.29%)
Vor Biopharma Inc (VOR) is a biotechnology company listed on NASDAQ. It is led by Jean-Paul Kress M.D., based in 500 Boylston Street, Boston, MA, United States, 02116, with about 76 employees. Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Net income was -$2.42B. VOR currently screens at market cap $813.9M.
Use this VOR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VOR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VOR SEC filings page. Lician reads the product cache first so this HTML stays unique to Vor Biopharma Inc even when a live quote feed is slow.
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
VOR Key Statistics
Market Cap
$813.87M
Volume
1.22M
Previous Close
$22.71
Day Range
$23.02 – $24.45
P/B Ratio
0.66
EPS
-$1.70
Revenue
$0.00
Net Income
-$116.91M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
76
VOR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$116.91M | -$117.86M | -$92.09M | -$68.90M |
| EPS (Diluted) | -$1.70 | -$1.75 | -$2.33 | -$2.10 |
Total Assets
$142.89M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$81.95M
Operating Cash Flow
-$99.66M
Free Cash Flow
$0.00
Vor Biopharma Inc Company Information
- Chairman, President & CEO
- Jean-Paul Kress M.D.
- Headquarters
- 500 Boylston Street, Boston, MA, United States, 02116
- Website
- www.vorbio.com
- Phone
- 617 655 6580
- IPO / Founded
- 2021-02-05
- Sector
- Healthcare
- Industry
- Biotechnology